Amgen presents new cost‑effectiveness and long‑term outcome data for Repatha at AHA 2026
Amgen disclosed fresh analyses of its cholesterol‑lowering antibody Repatha at the American Heart Association Scientific Sessions. An independent health‑economic study found the drug’s cost about 36% below the ACC/AHA benchmark, while clinical follow‑ups showed a 39% reduction in three‑point major adverse cardiovascular events for chronic‑kidney‑disease patients and a 29% lower event rate over more than eight years in the broader ASCVD population. The company highlighted the high unmet need, noting a heart attack occurs in the U.S. every 40 seconds, most of them first‑time events.
Why it matters
The company says the cost‑effectiveness finding could expand reimbursement and adoption of Repatha in high‑risk groups, potentially boosting future sales. The long‑term outcome data suggest sustained clinical benefit, which may strengthen the product’s market positioning.
Key facts
- 1Repatha was estimated to be cost‑effective at roughly 36% below the ACC/AHA cost‑effectiveness benchmark. prnewswire.com
- 2Patients with chronic kidney disease and no prior heart attack or stroke have about a 90% higher rate of coronary death, heart attack or ischemic stroke compared with those without CKD. rttnews.com
- 3Over a median follow‑up of 4.6 years, Repatha reduced three‑point MACE by 39% in CKD patients. rttnews.com
- 4In the same CKD cohort, Repatha lowered four‑point MACE by 23% and all‑cause mortality by 29%. rttnews.com
- 5In a long‑term analysis of FOURIER and its open‑label extension, Repatha was associated with a 29% lower rate of three‑point MACE over more than 8 years. rttnews.com
- 6The analysis also showed a 25% lower risk of cardiovascular death in the same long‑term cohort. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.